The indication must align: Wegovy-to-Zepbound is an obesity-to-obesity switch, while Ozempic-to-Mounjaro is a diabetes-to-diabetes switch
Fast Shipping: Medication is dispatched quickly and arrives in just days
Dual Agonist Comparison Detailed structural comparison of Retatrutide, a 39-amino-acid triple agonist targeting GLP-1, GIP, and glucagon receptors (~4813 Da), versus Tirzepatide, a 39-amino-acid dual GLP-1/GIP agonist (~4810 Da)
Careful patient selection, monitoring, and gradual dose titration are essential for safe use
A spokesperson from the pharmaceutical company told The Observer : Novo Nordisk will continue to evaluate its evidence package to support a future submission on semaglutide for managing overweight and obesity in young people aged 12 to 17. i revealed last week that Saxenda, Wegovy and Ozempic were being promoted for sale by users in weight-loss groups on Facebook as people scramble to get the drugs before they are available on the NHS
